LBP AIEC01
Alternative Names: LBP-AIEC01Latest Information Update: 27 Sep 2024
At a glance
- Originator Locus Biosciences
- Class Anti-inflammatories; Bacteriophages
- Mechanism of Action Bacterial DNA degraders; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Inflammatory bowel diseases
Highest Development Phases
- Research Inflammatory bowel diseases
Most Recent Events
- 05 Sep 2024 LBP AIEC01 is available for licensing as of 05 Sep 2024. https://live-locus-bioscience.pantheonsite.io/contact/
- 05 Sep 2024 Early research in Inflammatory bowel diseases in USA (unspecified route) (Locus Biosciences pipeline, September 2024)
- 17 Jul 2018 Locus Bioscience holds the exclusive global licensee of the foundational CRISPR-Cas3 patent estate from North Carolina State University and Duke University